EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) kicked off on Friday, up 1.43% from the previous trading day, before settling in for the closing price of $5.60. Over the past 52 weeks, EYPT has traded in a range of $3.91-$13.98.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 18.73% over the last five years. While this was happening, its average annual earnings per share was recorded -28.06%. With a float of $59.89 million, this company’s outstanding shares have now reached $68.81 million.
The firm has a total of 165 workers. Let’s measure their productivity. In terms of profitability, gross margin is 93.29%, operating margin of -287.94%, and the pretax margin is -261.75%.
EyePoint Pharmaceuticals Inc (EYPT) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of EyePoint Pharmaceuticals Inc is 12.96%, while institutional ownership is 96.95%. The most recent insider transaction that took place on May 19 ’25, was worth 29,950. In this transaction Director of this company bought 5,000 shares at a rate of $5.99, taking the stock ownership to the 36,500 shares. Before that another transaction happened on May 16 ’25, when Company’s Director bought 5,000 for $5.81, making the entire transaction worth $29,050. This insider now owns 31,500 shares in total.
EyePoint Pharmaceuticals Inc (EYPT) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -28.06% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 0.51% during the next five years compared to 15.65% growth over the previous five years of trading.
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) Trading Performance Indicators
Take a look at EyePoint Pharmaceuticals Inc’s (EYPT) current performance indicators. Last quarter, stock had a quick ratio of 7.79. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.97.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.41, a number that is poised to hit -0.81 in the next quarter and is forecasted to reach -2.91 in one year’s time.
Technical Analysis of EyePoint Pharmaceuticals Inc (EYPT)
Analysing the last 5-days average volume posted by the [EyePoint Pharmaceuticals Inc, EYPT], we can find that recorded value of 0.61 million was lower than the volume posted last year of 0.8 million. As of the previous 9 days, the stock’s Stochastic %D was 42.09%. Additionally, its Average True Range was 0.47.
During the past 100 days, EyePoint Pharmaceuticals Inc’s (EYPT) raw stochastic average was set at 31.66%, which indicates a significant increase from 24.30% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 69.68% in the past 14 days, which was lower than the 83.51% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.92, while its 200-day Moving Average is $7.80. Now, the first resistance to watch is $5.77. This is followed by the second major resistance level at $5.86. The third major resistance level sits at $6.01. If the price goes on to break the first support level at $5.52, it is likely to go to the next support level at $5.37. Should the price break the second support level, the third support level stands at $5.28.
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) Key Stats
The company with the Market Capitalisation of 390.85 million has total of 68,811K Shares Outstanding. Its annual sales at the moment are 43,270 K in contrast with the sum of -130,870 K annual income. Company’s last quarter sales were recorded 24,450 K and last quarter income was -45,200 K.
